| Code | CSB-RA006163MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Evalstotug, designed for research applications targeting CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4). CTLA4 is a critical immune checkpoint receptor expressed on T cells that functions as a negative regulator of T cell activation and proliferation. By competing with the costimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells, CTLA4 delivers inhibitory signals that dampen immune responses. This regulatory mechanism is essential for maintaining immune homeostasis and self-tolerance. Dysregulation of CTLA4 signaling is implicated in autoimmune diseases, while tumors exploit this pathway to evade immune surveillance, making it a significant target in immuno-oncology research.
Evalstotug represents an investigational anti-CTLA4 therapeutic antibody developed to modulate immune checkpoint activity. This biosimilar provides researchers with a reliable tool for investigating CTLA4-mediated immune regulation, studying T cell exhaustion mechanisms, exploring combination immunotherapy strategies, and evaluating checkpoint blockade effects in preclinical models of cancer and autoimmune disorders.
There are currently no reviews for this product.